Janus Henderson Group PLC Acquires 3,800 Shares of RxSight, Inc. (NASDAQ:RXST)

Janus Henderson Group PLC boosted its holdings in RxSight, Inc. (NASDAQ:RXST) by 35.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,500 shares of the company’s stock after purchasing an additional 3,800 shares during the period. Janus Henderson Group PLC’s holdings in RxSight were worth $716,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. CWM LLC boosted its holdings in shares of RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares during the last quarter. Raymond James & Associates purchased a new stake in shares of RxSight during the 2nd quarter worth approximately $3,549,000. Sara Bay Financial increased its stake in shares of RxSight by 1.0% during the 2nd quarter. Sara Bay Financial now owns 108,021 shares of the company’s stock worth $6,500,000 after purchasing an additional 1,045 shares during the last quarter. Summit Global Investments bought a new stake in shares of RxSight in the 2nd quarter worth approximately $628,000. Finally, Baillie Gifford & Co. lifted its stake in RxSight by 438.8% in the second quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock valued at $21,554,000 after purchasing an additional 291,733 shares during the last quarter. Institutional investors own 78.78% of the company’s stock.

RxSight Stock Up 3.9 %

Shares of RXST opened at $37.30 on Friday. RxSight, Inc. has a twelve month low of $34.92 and a twelve month high of $66.54. The stock has a market cap of $1.50 billion, a PE ratio of -44.94 and a beta of 1.11. The business’s 50-day moving average price is $46.98 and its 200-day moving average price is $50.79.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Wells Fargo & Company restated an “equal weight” rating and issued a $42.00 target price (down from $56.00) on shares of RxSight in a research note on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. UBS Group assumed coverage on shares of RxSight in a research note on Friday, December 6th. They issued a “buy” rating and a $52.00 target price for the company. Finally, Jefferies Financial Group assumed coverage on shares of RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $62.13.

Insider Buying and Selling

In other RxSight news, Director Shweta Maniar sold 3,782 shares of RxSight stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total transaction of $173,518.16. Following the transaction, the director now directly owns 10,902 shares of the company’s stock, valued at approximately $500,183.76. This trade represents a 25.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Ilya Goldshleger sold 3,105 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $46.08, for a total transaction of $143,078.40. Following the completion of the sale, the insider now directly owns 42,246 shares of the company’s stock, valued at $1,946,695.68. This trade represents a 6.85 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,807 shares of company stock valued at $3,202,275. Company insiders own 9.36% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.